Cargando…
In vivo cortical glutathione response to oral fumarate therapy in relapsing-remitting multiple sclerosis: A single-arm open-label phase IV trial using 7-Tesla (1)H MRS
BACKGROUND: This is an open-label, single-arm, single-center pilot study using 7-Tesla in vivo proton magnetic resonance spectroscopy ((1)H MRS) to measure brain cortical glutathione concentration at baseline before and during the use of oral fumarates as a disease-modifying therapy for multiple scl...
Autores principales: | Juchem, Christoph, Swanberg, Kelley M., Prinsen, Hetty, Pelletier, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480324/ https://www.ncbi.nlm.nih.gov/pubmed/37651844 http://dx.doi.org/10.1016/j.nicl.2023.103495 |
Ejemplares similares
-
Multiple sclerosis diagnosis and phenotype identification by multivariate classification of in vivo frontal cortex metabolite profiles
por: Swanberg, Kelley M., et al.
Publicado: (2022) -
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020) -
Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017) -
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
por: Lundy, Steven K., et al.
Publicado: (2016) -
Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
por: Ozel, Osman, et al.
Publicado: (2019)